Keyphrases
Human Plasma
100%
Nanoparticles
100%
CRLX101
100%
Camptothecin
100%
Nanoparticle-drug Conjugate
20%
Tumor
10%
Clinical Outcomes
10%
Advanced Prostate Cancer
10%
Early Phase Clinical Trials
10%
Room Temperature
10%
Drug Interactions
10%
Plasma Concentration
10%
Drug Delivery
10%
Clinical Activity
10%
Physicochemical Properties
10%
Clinical Samples
10%
Clinical Utility
10%
Drug Exposure
10%
Anticancer Agents
10%
Pharmacodynamic Biomarker
10%
Hypoxia-inducible factor-1α (HIF-1α)
10%
National Cancer Institute
10%
Analytical Method
10%
Topoisomerase
10%
Combination Treatment
10%
Specimen Preparation
10%
Plasma Pharmacokinetics
10%
Potent Inhibitor
10%
Phase II Clinical Trial
10%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
10%
Two-sample
10%
Solid-phase Extraction
10%
Freeze-thaw Cycles
10%
I(1)
10%
Solubility-pH
10%
Ultra HPLC
10%
Dynamic Calibration
10%
Lactone Ring
10%
Outcome Biomarkers
10%
Pharmacology, Toxicology and Pharmaceutical Science
Nanoparticle
100%
Camptothecin
100%
Clinical Trial
20%
Drug Conjugate
20%
Neoplasm
10%
Malignant Neoplasm
10%
Biological Marker
10%
Drug-Drug Interaction
10%
Pharmacodynamics
10%
Anticarcinogen
10%
High Performance Liquid Chromatography
10%
Prostate Cancer
10%
Lactone
10%
DNA Topoisomerase
10%
Pharmacokinetics
10%